Genmab A/S (GMAB) Reports 75%/67% ORR in Phase 2 mCRC

Genmab reported updated Phase 2 data for petosemtamab plus chemo in metastatic colorectal cancer, showing 75% ORR in 1L and 67% in 2L, with 81% in 1L left-sided tumors. Median follow-up was 5.9 and 7.1 months. Most responses were confirmed. This update supports Genmab’s shift into late-stage GI oncology.

Original reporting
Published Oct 25, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Genmab A/S (GMAB) Reports 75%/67% ORR in Phase 2 mCRC — source image
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

Positive ORR could accelerate partnership talks and boost valuation.

02

Market read

First disclosure of strong Phase 2 efficacy data for a colorectal cancer candidate.

03

What to watch

Long‑term safety and regulatory timeline remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab is pivoting into late‑stage GI oncology; Phase 2 data is a key milestone.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab reported Phase 2 ORR 75%/67% for petosemtamab in metastatic colorectal cancer.

Expected impact

likely upward pressure as market prices in the positive trial data

Evidence & confidence

Phase 2 data with high ORR is material for a biotech and can drive short‑term buying.

Market effects

reinforces optimism for GI oncology pipelines and may lift peer biotech valuations.

European biotech sector could see modest gains.

limited to biotech investors; no broad market effect.

Counterpoint

Data may not translate to Phase 3 success; caution on over‑optimism.

Key entities

  • Genmab A/S

    Danish biotech developing antibody therapeutics.

Related articles

$GMABHighAI 8/10

Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

$GMABMedAI 8/10

Why is Genmab stock sliding today?

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.